Targets and Emerging Therapies for Schizophrenia
New and emerging directions in pharmaceutical research to better treat schizophrenia Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. Targets and Emerging Therapies for Schi…
Mehr
CHF 138.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Wood, Michael W. (Hrsg.)
- ISBN: 978-1-118-30938-4
- EAN: 9781118309384
- Produktnummer: 13828451
- Verlag: Wiley
- Sprache: Englisch
- Erscheinungsjahr: 2012
- Seitenangabe: 486 S.
- Plattform: PDF
- Masse: 22'125 KB
Über den Autor
JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies. MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.
1 weiteres Werk von Jeffrey S. Albert:
Bewertungen
Anmelden